Journal of Clinical Medicine (Feb 2022)

Circulating SPINT1 Is Reduced in a Preeclamptic Cohort with Co-Existing Fetal Growth Restriction

  • Ciara N. Murphy,
  • Catherine A. Cluver,
  • Susan P. Walker,
  • Emerson Keenan,
  • Roxanne Hastie,
  • Teresa M. MacDonald,
  • Natalie J. Hannan,
  • Fiona C. Brownfoot,
  • Ping Cannon,
  • Stephen Tong,
  • Tu’uhevaha J. Kaitu’u-Lino

DOI
https://doi.org/10.3390/jcm11040901
Journal volume & issue
Vol. 11, no. 4
p. 901

Abstract

Read online

Fetal growth restriction (FGR), when undetected antenatally, is the biggest risk factor for preventable stillbirth. Maternal circulating SPINT1 is reduced in pregnancies, which ultimately deliver small for gestational age (SGA) infants at term (birthweight n = 75, median = 18,857 pg/mL, IQR 10,782–29,890 pg/mL, p n = 22, median = 40,168 pg/mL, IQR 22,342–75,172 pg/mL). This was confirmed in the Preeclampsia Intervention 2 with metformin trial where levels of SPINT1 in maternal circulation were reduced in SGA pregnancies (n = 95, median = 57,764 pg/mL, IQR 42,212–91,356 pg/mL, p n = 40, median = 107,062 pg/mL, IQR 70,183–176,532 pg/mL). Placental Growth Factor (PlGF) and sFlt-1 were also measured. PlGF was significantly reduced in the SGA pregnancies, while ratios of sFlt-1/SPINT1 and sFlt1/PlGF were significantly increased. This is the first study to demonstrate significantly reduced SPINT1 in co-existing FGR and preeclamptic pregnancies.

Keywords